[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
June 7, 2006

Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials—Correction

JAMA. 2006;295(21):2482. doi:10.1001/jama.295.21.2482-c

Incorrect Statements on Funding/Support and Role of the Sponsors and Incorrect and Incomplete Financial Disclosures: In the Review entitled “Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials” published in the May 17, 2006, issue of JAMA (2006;295:2275-2285), the following errors appeared:

After this issue was printed and mailed, JAMA was informed by the authors that information reported on page 2284 of the article was incorrect.

The Funding/Support statement should have read “This study was supported by the Mayo Foundation. Additional data were provided by Abbott and Centocor. Data provided by Abbott were subject to a confidentiality agreement.”

The Role of the Sponsors statement should have read “Abbott and Centocor did not have any role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation or approval of the manuscript. The manuscript was sent to Abbott for review prior to submission for publication.”

The Financial Disclosures statement should have read: “Dr Bongartz reported that he has given lectures for Abbott as part of seminars for study nurses and received honorarium in the form of a medical textbook for the Internal Medicine library; he received an educational grant from Amgen in February 2006 to perform the same type of analysis of harmful events under anti-TNF treatment for etanercept; and he received the 2005 Fellow's Award of the American College of Rheumatology, which was supported by Amgen.”

Dr Matteson reported that he has been a paid consultant for Centocor for work unrelated to this study and has been working with Wyeth and Amgen to perform a similar analysis for etanercept; he has been an Investigator for the American College of Rheumatology, Amgen, Asta, Biogen-IDEC, Burroughs-Wellcome, Centocor, Cypress, Endocyte Inc, Genentech, Hoffmann-LaRoche, Human Genome Sciences, Immunex, Protein Design Laboratories, Nastech, Pharmacia & Upjohn, Schering, Wyeth, and Xoma Corp; he has received grant support from Amgen, Aventis, Centocor/Johnson & Johnson, Genentech, Immunex, Mayo Foundation, Novartis, and the National Institutes of Health; and he has been a consultant for Amgen, BoneandJoint.org, Burroughs-Wellcome, Centocor, Regeneron, Takeda, Upjohn, Watermark Research, and the Vasculitis Foundation.”

This correction was published online on May 16, 2006. Because of the nature and extensiveness of this incorrect and incomplete reporting, JAMA has requested that the Mayo Clinic College of Medicine conduct an investigation. JAMA will publish another correction or clarification once the results of that investigation become available.

×